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1344Secukinumab for moderate-to-severe
palmoplantar pustular psoriasis: Results
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Christian Sieder, PhD,e Roberto Orsenigo, MD,f and Kamel Chaouche-Teyara, PhDe
Kiel, Germany; Paris, France; Glasgow, United Kingdom; Basel, Switzerland; and Origgio, ItalyBackground: Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that
is resistant to treatment. Secukinumab, an antieinterleukin 17A monoclonal antibody, is highly efficacious
in the treatment of moderate-to-severe psoriasis.Objective: The primary objective was to determine the rate of achievement of a 75% improvement from
baseline in Palmoplantar Psoriasis Area and Severity Index (PPPASI75) with secukinumab at week 16 versus
with placebo (at a 2.5% significance level).Methods: 2PRECISE was a phase 3b multicenter, randomized, double-blind, placebo-controlled,
parallel-group study comparing treatment with 300 mg of secukinumab (n = 79), 150 mg of secukinumab
(n = 80), and placebo (n = 78) in subjects with moderate-to-severe PPP over a period of 52 weeks.Results: The primary end point was not met. At week 16, 26.6% of subjects treatedwith 300mg of secukinumab
achieved PPPASI75 versus 14.1% of those who received placebo (P = .0411) (odds ratio, 2.62; 95% confidence
interval, 1.04-6.60). At week 52, 41.8% of subjects treated with 300 mg of secukinumab had achieved
ppPASI75. More Dermatology Life Quality Index responses of 0 or 1 were achieved with 300mg of secukinumab
(13.0%) than with placebo (4.3%) at week 16. At week 52, 43.1% of subjects receiving 300 mg of secukinumab
had a Dermatology Life Quality Index response of 0 or 1. No unexpected adverse events were observed.Limitations: Small sample size and characteristics of the PPP disease course.Conclusion: Patients with PPP who were treated with secukinumab, 300 mg, showed benefit in terms of
PPPASI75 responses over 52 weeks and improved quality of life. ( J Am Acad Dermatol 2019;80:1344-52.)
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Mrowietz et al 1345Palmoplantar pustular psoriasis (PPP) is a
debilitating disease of the palms and/or soles that is
resistant to treatment.1 PPP causes a high disease
burden and working disability, and it has a high
impact on health-related quality of life.2
Whether PPP is a unique disease entity or a
subphenotype of psoriasis is debated.3 Both condi-CAPSULE SUMMARY
d Palmoplantar pustular psoriasis is
chronic, disabling, and resistant to
treatment.
d The 2PRECISE randomized controlled
trial shows potential benefits of
secukinumab in the treatment of
palmoplantar pustular psoriasis over
52 weeks, with improved quality of life
and no unexpected adverse events.tions display dysregulated in-
flammatory pathways, 20%
of subjects with PPP have
concomitant plaque psoria-
sis, and the 2 conditions have
shared histologic features.4
The pathogenesis of PPP
remains unclear, but the
skin’s innate immune system
may be important. The level
of neutrophil-attracting che-
mokine interleukin 8 (IL-8) is
increased in PPP.5 The anti-
microbial peptide LL-37 and
its precursors are implicated
in pathogenesis of PPP and up-regulate the
cytokines IL-1, IL-8, IL-23, and IL-17.6,7 PPP can
associate with HLA-B27 gene but not with the major
plaque psoriasis gene HLA-Cw6.8 IL-17Aetargeted
genes are also up-regulated in PPP, indicating a
potential role of IL-17A in its pathophysiology.9
Recent studies identified 3 distinct subsets of PPP
subjects with interleukin 36 receptor agonist gene
(IL36RN ), adaptor related protein complex 1 subunit
sigma 3 gene (AP1S3), and caspase recruitment
domain family member 14 gene (CARD14)
mutations, which up-regulated the IL-36 pathway,
favoring the differentiation of type 17 helper
T cells.10-12
PPP is resistant to treatment, with high rates of
recurrence. Drugs tested in PPP include colchicine,
itraconazole, alitretinoin, and biologics (including
ustekinumab and guselkumab).13-15 There are
limited guidelines for treatment of PPP, but
management algorithms have been proposed.3
Secukinumab, which is a fully humanmonoclonal
antibody that selectively targets IL-17A, is highly
efficacious in the treatment of moderate-to-severe
plaque psoriasis, with a sustained effect and a
favorable safety profile.16,17 Secukinumab is
effective in generalized pustular psoriasis, which
shares characteristics with PPP, and also in
nonpustular palmoplantar psoriasis.18-21 Epidermal
neutrophils disappear shortly after initiation of
secukinumab treatment.22 Therefore, targeting
IL-17A with secukinumab may be beneficial for PPP.
The2PRECISEstudyaimed to investigate theefficacy
and safety of secukinumab in treatment-refractory PPPin a multinational, randomized, placebo-controlled
clinical trial.
METHODS
Study design and participants
2PRECISE (CAIN457A3301; NCT02008890
registration on December 11, 2013; EuropeanClinical Trials database
No. 2013-003086-34) was
a phase 3b multicenter,
randomized, double-blind,
placebo-controlled, parallel-
group study comparing
2 doses of secukinumab
with placebo in subjects
with moderate-to-severe
PPP (Fig 1). Subjects were
randomized 1:1:1 to 300 mg
of secukinumab, 150 mg of
secukinumab, or placebo for
16 weeks (treatment period 1
[TP1]). Randomization wascarried out by using interactive response technology.
Subjects who completed TP1 continued to week 52
in treatment period 2 (TP2), wherein nonresponders
to placebo were rerandomized to secukinumab,
300 mg, or secukinumab, 150 mg (Fig 1). Patients
who completed TP2 were offered participation in an
extension study from week 52 to week 148 (those in
the group with a response to placebo were not
eligible). Blinding of investigators and subjects was
maintained to week 52.
The study protocol was reviewed by the
independent ethics committee/institutional review
board for each center, and the trial was
conducted according to the Declaration of Helsinki.
Written informed consent was obtained from all
subjects.
Subjects aged 18 years or older with moderate-
to-severe chronic PPP (a baseline Palmoplantar
Psoriasis Area and Severity Index [PPPASI]23 of
$12 and a Dermatology Life Quality Index
[DLQI] of $10) were enrolled. The PPPASI is a
modification of the PASI with evaluation of ery-
thema, vesicles/pustules, and scaling/desquama-
tion. Subjects had to have a diagnosis of PPP
for at least 6 months before randomization, with
confirmed presence of pustules in the past
6 months if not present at screening. Subjects
who had erythrodermic or guttate psoriasis or
had generalized pustular psoriasis were excluded.
All subjects were candidates for systemic therapy
(PPP inadequately controlled by topical treatment,
phototherapy, and/or previous systemic therapy).
Subjects with concomitant plaque psoriasis were
Abbreviations used:
AE: adverse event
DLQI: Dermatology Life Quality Index
IL: interleukin
OR: odds ratio
PPP: palmoplantar pustular psoriasis
PPPASI75: 75% improvement from baseline in
palmoplantar Psoriasis Area and
Severity Index score
TP1: treatment period 1
TP2: treatment period 2
WPAI-PSO: Work Productivity and Activity
Impairment Questionnaire-Psoriasis
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IL-17etargeting biologics was permitted. Use of
other systemic treatments or ultraviolet therapy was
not permitted during the study; the washout period
was between 2 weeks and 6 months depending on
the therapy.
Procedures
In TP1, secukinumab, 300 mg or 150 mg, or
placebo was administered at baseline; at weeks 1,
2, 3, and 4; and then at 4-week intervals. In TP2,
placebo subjects who were rerandomized to
secukinumab treatment received weekly injections
of secukinumab, 300 mg or 150 mg, for 5 weeks
followed by administration every 4 weeks.
Secukinumab was self-administered subcutaneously
with use of a prefilled syringe.24
Study objectives
The primary objective of the 2PRECISE study
was to demonstrate the superiority of secukinumab,
300 mg and/or 150 mg, compared with placebo in
subjects with moderate-to-severe chronic PPP at
week 16, as measured by difference in the rate of
achievement of a 75% improvement from baseline in
palmoplantar Psoriasis Area and Severity Index
(PPPASI75).
The main secondary end point was the mean
change from baseline PPPASI with secukinumab,
300 mg or 150 mg, compared with placebo at week
16. Other secondary end points were the time course
of PPPASI response rates and the safety and
tolerability of secukinumab.
Exploratory outcomes included PPPASI response
in subjects with or without concomitant plaque
psoriasis or previous systemic or biologic
therapy. Biopsies were not performed in this
study. Patient-reported outcomes were assessed
by using the DLQI,25 the Palmar-Pustular Quality
of Life Index, and the Work Productivity and Activity
Impairment Questionnaire-Psoriasis (WPAI-PSO).Statistical analysis
For a PPPASI75 response rate of 47% with
secukinumab, 300 mg, and 20% response with
placebo, 70 subjects per arm would result in 90%
power to detect a significant difference.
Efficacy analyses were based on the full analysis
set, comprising all subjects to whom study treatment
was assigned. Safety analyses were performed on all
subjects who received at least 1 dose of study
treatment.
The primary analysis was conducted on the full
analysis set via logistic regression that included
treatment and presence versus absence of
plaque-type psoriasis as factors. Subjects with
missing PPPASI assessments at week 16 were
considered responders if they met the response
criteria by the time of dropout; otherwise, they
were considered nonresponders (last observation
carried forward). To address multiplicity, the 2
primary hypotheses were tested by using a
Bonferroni-Holm procedure: if the smaller of the 2
P values obtained from the logistic regression model
was less than or equal to 2.5%, then the comparison
was regarded as significant. Multiple and
nonresponder imputation sensitivity analyses were
also performed.
Absolute change from baseline to week 16 of the
PPPASI was analyzed by using analysis of
covariance. A further logistic regression model was
used to compare PPPASI response over time for
secukinumab-treated and placebo-treated subjects.
Absolute change from baseline of DLQI total
score during TP1 was analyzed by analysis of
covariance for all pairwise comparisons between
the secukinumab treatment groups and the placebo
group.
RESULTS
Subject disposition
Data were collected between December 26, 2013
(the date of first patient’s first visit), and January 20,
2016 (the data cutoff date). Overall, 237 subjects from
61 centers were enrolled in the study. In TP1, 79
were randomized to receive secukinumab 300 mg,
80 to receive secukinumab 150 mg, and 78 to receive
placebo (Fig 1). Baseline characteristics were
balanced between treatment groups (Table I). A total
of 195 subjects (82.3%) completed 16 weeks of
treatment (Fig 1). AEs were the most common reason
for discontinuation between week 1 and week 16
(Fig 1).
In TP2, 92 subjects in each group received
secukinumab, 300 mg, and secukinumab, 150 mg
(including placebo nonresponders [Fig 1]). There
were 65 (33.5%) discontinuations between weeks 16
Fig 1. 2PRECISE study design and patient disposition. This was a phase 3b multicenter,
randomized, double-blind, placebo-controlled, parallel-group study. AE, Adverse event;
TP2, treatment period 2.
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Table I. Baseline characteristics
Characteristic Secukinumab, 300 mg (n = 79) Secukinumab, 150 mg (n = 80) Placebo, (n = 78)
Sex, n (%)
Female 64 (81.0) 63 (78.8) 59 (75.6)
Male 15 (19.0) 17 (21.3) 19 (24.4)
Mean age 6 SD, y 50.6 6 14.8 50.7 6 13.7 52.9 6 11.3
Race, n (%)
Black 0 (0.0) 1 (1.3) 1 (1.3)
White 78 (98.7) 78 (97.5) 76 (97.4)
Missing 0 (0.0) 1 (1.3) 1 (1.3)
Other 1 (1.3) 0 (0.0) 0 (0.0)
Weight
Mean 6 SD, kg 79.0 6 18.0 79.1 6 16.6 78.2 6 17.7
\90 kg, n (%) 62 (78.5) 62 (77.5) 62 (79.5)
$90 kg, n (%) 17 (21.5) 18 (22.5) 16 (20.5)
Smoking status, n (%)
Current 48 (60.8) 48 (60.0) 45 (57.7)
Former 21 (26.6) 22 (27.5) 26 (33.3)
Never 10 (12.7) 10 (12.5) 7 (9.0)
Mean baseline PPPASI 6 SD 23.0 6 10.3 23.1 6 9.9 23.6 6 10.3
Plaque-type psoriasis, n (%)
Yes 34 (43.0) 38 (47.5) 36 (46.2)
No 45 (57.0) 42 (52.5) 42 (53.8)
Mean baseline PASI score for subjects
with plaque-type psoriasis 6 SD
4.4 6 4.7 4.0 6 3.6 4.1 6 4.7
Mean baseline DLQI 6 SD 16.2 6 5.1 17.1 6 5.4 16.8 6 5.7
Mean baseline SGA 6 SD 31.2 6 21.9 32.7 6 22.7 30.9 6 20.7
Mean time since occurrence of PPP 6 SD
(calculated as years between start date
and date of screening visit)
8.0 6 8.8 9.5 6 9.5 10.3 6 12.0
DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PPP, palmoplantar pustular psoriasis; PPPASI, 75% improvement
from baseline in palmoplantar Psoriasis Area and Severity Index; SD, standard deviation score; SGA, Subject’s Global Assessment.
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Fig 2. Proportion of subjects (full analysis set 1, all
patients, last observation carried forward) achieving a
75% improvement from baseline in the Palmoplantar
Psoriasis Area Severity Index score (PPPASI75) through
week 16. The primary end point was not met, but clinical
benefit was observed with secukinumab, 300 mg, with
26.6% of subjects achieving PPPASI75 at week 16.
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group than in the 300-mg group, with the most
common reasons for withdrawal being adverse
events (AEs) or subject decision (Fig 1).
PPPASI75 response rates to week 16
At week 16, a PPPASI75 response was achieved in
26.6% of subjects treated with 300 mg of
secukinumab (21 of 79) versus in 14.1% who
received placebo (11 of 78) (P = .0411) and in
17.5% of those treated with 150 mg of secukinumab
(14 of 80) (P = .5722) (Fig 2). The superiority of
secukinumab, 300 mg, over placebo did not reach
the 2.5% significance threshold; however, an odds
ratio (OR) of 2.62 (95% confidence interval,
1.04-6.60) favoring 300 mg of secukinumab over
placebo was calculated.
Similar results were seen with use of multiple and
nonresponder imputation. The multiple response
imputation results for missing PPPASI values were an
OR of 2.42 and a P value of .0634, and the last
observation carried forward (obtained when data
were analyzed by nonresponder imputation) resultswere an OR of 2.72 with a 95% confidence interval of
1.06 to 7.00.
Excluding subjects from the efficacy analysis by
prespecified criteria (where visit 9 was not at week
16, with missing PPPASI at visit 9, and with any
35.0
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Fig 3. Improvements in the rate of achievement of a 75%
improvement from baseline in the Palmoplantar Psoriasis
Area Severity Index (PPPASI75) with secukinumab were
observed to continue to week 52.
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300 mg of secukinumab and placebo of 3.69 and a
P value of 0.0150.
A 50% improvement from baseline in PPPASI
was achieved by 52.2% of subjects treated with
secukinumab, 300 mg, at week 16 (36 of 69) versus
by 32.9% of those receiving placebo (23 of 70)
(P = .0159).
Mean change from baseline of PPPASI to week
16
Themean change in PPPASI frombaseline toweek
16 was 30.2% for secukinumab, 300 mg, versus
26.7% for placebo (9.74 vs 6.73) (P = .1576).
Time course of PPPASI response
The proportion of responders in the group treated
with secukinumab, 300mg, increased betweenweek
8 (13.3% [10 of 75]) and week 16 (26.6% [21 of 79])
(Fig 2, A).
At week 52, a PPPASI75 response was achieved
in 41.8% of subjects treated with 300 mg of
secukinumab (33 of 79) versus in 35.0% of subjects
treatedwith 150mg of secukinumab (28 of 80) (Fig 3).
PPPASI response in subjects with plaque
psoriasis and previous therapy
At week 16, a PPPASI75 response was achieved in
22.2% of subjects without concomitant plaque
psoriasis who received secukinumab, 300 mg, versus
in 9.5% of those in the placebo group. In subjects
with concomitant plaque psoriasis, the PPPASI75
response rates were 32.4% in those treated with
secukinumab, 300 mg, versus in 19.4% of those who
received placebo.
Among subjects who had received previous
systemic therapy for PPP, 28.6% of those in the group
treated with secukinumab, 300 mg, and 14.8% of
those in the placebo group achieved a PPPASI75
response at week 16. In comparison, among subjects
without prior systemic therapy, a PPPASI75 response
at week 16 was achieved by 21.7% of those in the
group treated with secukinumab, 300 mg, versus by
12.5% of those in the placebo group.
The rate of ppPASI75 response was also analyzed
for subjects who had failure of a previous biologic
therapy. In these subjects, PPPASI75 response was
higher at week 16 in those subjects receiving 300 mg
of secukinumab (42.9%) than in those receiving
placebo (14.3%).
Subject-reported outcomes
More scores of DLQI 0 or 1 were achieved with
300 mg of secukinumab (13.0%) than with placebo(4.3%) at week 16. At week 52, the proportion of
subjects with a DLQI of 0 or 1 was considerably
higher for those treated with secukinumab, 300 mg,
than for those in all the other groups.
Subjects receiving secukinumab, 300 mg, showed
consistently greater reductions in WPAI-PSO
components (presenteeism, work productivity loss,
and total activity impairment) at week 16 (compared
with placebo) and at week 52.Safety
The safety of secukinumab has been well
established in phase 3 clinical trials in plaque
psoriasis, with no appreciable differences between
the 150-mg and 300-mg doses; the most frequent AEs
were nasopharyngitis and upper respiratory tract
infections, with a low incidence of AEs of special
interest (ie, serious infections, malignancy, major
adverse cardiovascular events, and Crohn’s
disease).26 The safety profile of secukinumab was
consistent with that in previous phase 3 trials, and no
new or unexpected safety signals were observed.
There were no deaths but 14 serious AEs (8 in
subjects receiving 300 mg of secukinumab, 1 in a
subject receiving 150 mg of secukinumab, and 5 in
those given placebo) (Table II). The most frequent
AEs were nasopharyngitis, pustular psoriasis,
headache, and pruritus (the incidence rates per 100
patient-years for subjects receiving secukinumab,
300 mg, were 50.3, 30.5, 16.1, and 15.1, respectively)
(Table II).
Tonsil cancer was reported in 1 subject who
received placebo but was switched to secukinumab,
300mg, and cerebrovascular accident was reported 1
subject who received placebo during TP1. Neither
event was suspected of being related to the study
drug.
Table II. Summary of AEs through week 52 (the entire treatment period)
AE
Secukinumab,
300 mg (n = 79)
Secukinumab,
150 mg (n = 80)
Placebo
(n = 78)
All secukinumab,
300 mg (n = 107)
All secukinumab,
150 mg (n = 107)
Any AE, n (%) 74 (93.7) 76 (95.0) 59 (75.6) 95 (88.8) 96 (89.7)
SAE, n (%) 10 (12.7) 4 (5.0) 5 (6.4) 13 (12.1) 5 (4.7)
Death 0 0 0 0 0
Most frequent treatment-emergent
adverse events by term,
IR per 100 patient-years
Nasopharyngitis 55.9 27.7 28.1 50.3 24.5
Pustular psoriasis 32.6 37.1 10.7 30.5 32.0
Headache 19.7 10.9 23.2 16.1 9.3
Pruritus 16.9 10.8 7.9 15.1 7.8
Psoriasis 11.5 10.6 10.0 8.5 10.3
Bronchitis 9.8 7.0 2.0 11.0 6.3
Cough 11.5 8.9 0.0 6.4 9.6
Folliculitis 11.8 7.1 1.9 9.9 5.1
Eczema 11.4 3.4 5.8 8.5 5.1
Pain in extremity 11.5 1.7 11.7 8.6 3.8
Back pain 9.9 5.3 7.7 7.4 3.8
Diarrhea 9.8 5.2 7.7 7.4 3.8
Nausea 8.3 3.5 0.0 7.3 3.8
Urinary tract infection 8.1 3.5 5.8 6.0 5.1
Arthralgia 4.8 5.2 9.7 3.6 5.2
AE, Adverse event; IR, incidence rate; SAE, serious adverse event.
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As PPP is a chronic debilitating condition, there is
a high unmet need for long-term therapeutic
options.
After 16 weeks of treatment there was clinical
improvement of PPP in the group treated with
secukinumab, 300 mg; however, the significance
threshold was not reached. The placebo response
rate in 2PRECISE was relatively high for a clinical
trial in psoriasis; however, a high proportion of
patients with PPP appeared to experience spon-
taneous remissions and the natural course of the
disease is not fully understood.27 To our knowl-
edge, efficacy similar to that seen at 52 weeks has
not been reported in this patient population for
any other treatment used in PPP to date.14,28
Secukinumab was well tolerated, with no new
or cumulative treatment-emergent AEs. The
slightly higher discontinuation rate as compared
with that in psoriasis trials with biologics,
including secukinumab, may be due to the dis-
ease characteristics of PPP; however, because of a
lack of similar clinical trials in PPP, there is no
direct comparison.
Response to secukinumab, 300 mg, was higher in
subjects with concomitant plaque psoriasis than
in those without. In subjects who received secuki-
numab throughout the 52-week period, response
was separated between those with or withoutconcomitant plaque psoriasis. There may be 2
distinct nosologic entities, which may explain why
the response of PPP to secukinumab is different than
that of plaque psoriasis. Genetic studies suggest that
PPP is distinct from plaque psoriasis; for instance,
PPP is associated with HLA-B27 but not with the
major plaque psoriasis gene HLA-Cw6.8 Subtypes of
PPP may also existdas evidenced by mutations
detected in 3 innate immunity genes, IL36RN,
AP1S3, and CARD1410-12dand these could respond
differently to treatment. The pronounced effect of
secukinumab on the signs and symptoms PPP after
52 weeks argues for a pathogenetic role of IL-17A in
PPP, which is supported by evidence that type 17
helper T cells and IL-17 cytokines play an important
role in PPP.9,29-31
Published guidance on treatment of PPP
highlights the importance of long-term disease
control.3 Therefore, the efficacy of secukinumab
after 52 weeks of treatment may constitute a more
meaningful time point. The difference between
secukinumab and placebo at week 16 was small;
this difference may also have arisen from variation in
the natural course of PPP, which is not fully
understood. The week 52 response to secukinumab,
300 mg, is relevant to clinical practice in this
treatment-refractory condition. This is supported by
a substantial improvement in health-related quality
of life, particularly in the context of the mean
J AM ACAD DERMATOL
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assessment of the WPAI-PSO showed major
improvements in presenteeism, work productivity
loss, and total activity impairment.
A secondary objective was to evaluate the time
course of PPPASI response rates between baseline
and week 16, and between week 16 and week 52. As
PPP is known to show fluctuations, the observations
for the placebo group may have arisen from the
natural course of the disease.
The 2PRECISE study was limited by its sample size,
which although large for PPP, was not comparable to
that in larger trials in plaque psoriasis. The primary
end point at week 16 may not fully match the
characteristics of the PPP disease course after initiation
of any treatment. Clinical experience shows that
clearing of PPP lesions may take longer than clearing
of psoriatic lesions elsewhere on the body. The
statistical analysis plan using a Bonferroni-Holm
strategy missed the stringent statistical significance
threshold after 16 weeks of secukinumab therapy
despite the clinical efficacy of the dose of 300 mg of
secukinumab. Additionally, use of the stringent pri-
mary end point of achievement of more than a 75%
improvement of PPPASI as compared with baseline
may not have been appropriate in a highly treatment-
resistant condition such as PPP.
A criterion standard of treatment for PPP does not
exist. Many drugs have shown no or limited benefits
in small sample sizes or subject case reports.13,14 In
the latest Cochrane Review of treatments for PPP,
only a few high-quality studies were identified, and
few of them used patient-reported outcomes.28
Therefore, any new therapeutic option suitable for
long-term control of PPP is of great interest.
The primary end point of secukinumab
superiority to placebo at week 16 in patients with
PPP was not met in 2PRECISE. However, the
reduction of PPPASI by 75% in more than 41% of
subjects and the achievement of a DLQI of 0 or 1 in
43% of subjects treated with secukinumab, 300 mg,
over 52 weeks in 2PRECISE represents potential
benefit in a difficult-to-treat condition.
Medical writing assistance was provided by Evelyn
Altemeyer, Novartis Ireland Ltd.
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